Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical Quality Assessment of paravertebral catheter placement in minimally invasive esophagectomy: an exploratory post hoc analysis of the PEPMEN- trial.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

A Systematic Review and Expert Evaluation of Perioperative SGLT2 Inhibitor-Associated Ketoacidosis Case Reports.

Acta anaesthesiologica Scandinavica·2026
Same author

Associations between estradiol levels and subjective sleep parameters in a large cohort of men and women.

Endocrine connections·2026
Same author

The effects of sleep improving interventions in medical hospital wards: the WEsleep study - A randomized clinical trial.

European journal of internal medicine·2025
Same author

Taste preference of patients shortly after surgery in the Post Anaesthesia Care Unit (PACU).

Clinical nutrition ESPEN·2025
Same author

From Endoscopic Inspection to Gene-Expression: A Thorough Assessment of the Duodenal Mucosa After Resurfacing-A Prospective Study.

Digestive diseases and sciences·2025
Same journal

RNA Sequencing Indicates Distinct Platelet Transcriptomic Changes in Immune Thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Joint effect of muscle strength and physical inactivity on risk of incident venous thromboembolism: The Tromsø Study.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

The Natural Mutation Arg221aTrp in Human α-Thrombin Abrogates Physiological Na<sup>+</sup> Binding and Preferentially Hinders the Protease Anticoagulant Functions.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

A historical review of the biological, semantic and clinical aspects of aspirin resistance.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Association between Thrombus Neutrophil Extracellular Traps Content and Ischemic Stroke Recurrence.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Peptide-Mediated Inhibition of Surface-Initiated Thrombogenesis.

Journal of thrombosis and haemostasis : JTH·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Hyperglycemia: a prothrombotic factor?

B A Lemkes1, J Hermanides, J H Devries

  • 1Department of Internal Medicine, Academic Medical Centre, Amsterdam, the Netherlands. b.a.lemkes@amc.uva.nl

Journal of Thrombosis and Haemostasis : JTH
|May 25, 2010
PubMed
Summary
This summary is machine-generated.

Diabetes increases the risk of blood clots due to hyperglycemia, impacting coagulation factors and fibrinolysis. Both acute and chronic high blood sugar levels create a prothrombotic state, worsening outcomes in thrombotic diseases.

Related Experiment Videos

Last Updated: Jun 12, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Area of Science:

  • Endocrinology
  • Hematology
  • Vascular Biology

Background:

  • Diabetes mellitus is linked to a higher incidence of atherothrombotic and venous thrombosis events.
  • A prothrombotic state in diabetes is evidenced by elevated coagulation factors and reduced fibrinolysis.
  • Hyperglycemia is a key contributor to these hemostatic abnormalities, with glycemic control influencing outcomes.

Purpose of the Study:

  • To investigate the prothrombotic effects of both chronic and acute hyperglycemia on the coagulation system.
  • To explore the mechanisms underlying hyperglycemia-induced prothrombotic shifts.
  • To assess the association between hyperglycemia and clinical outcomes in thrombotic diseases.

Main Methods:

  • Review of laboratory findings related to coagulation and fibrinolysis in diabetic patients.
  • Analysis of the impact of acute versus chronic hyperglycemia on hemostasis.
  • Examination of proposed mechanisms including oxidative stress, glycocalyx degradation, glycation, and hyperinsulinemia.

Main Results:

  • Laboratory data indicate a prothrombotic shift associated with both chronic and acute hyperglycemia.
  • Hyperglycemia, including stress-induced transient forms, correlates with poor outcomes in thrombotic conditions.
  • Proposed mechanisms involve hyperglycemia-induced oxidative stress, endothelial glycocalyx damage, factor glycation, and hyperinsulinemia.

Conclusions:

  • Evidence supports a prothrombotic shift due to chronic and acute hyperglycemia.
  • Hyperglycemia is associated with adverse clinical outcomes in thrombotic events.
  • Further research is needed to determine if intensive glycemic control can prevent hypercoagulability and improve outcomes.